These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 22295124)
1. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124 [TBL] [Abstract][Full Text] [Related]
2. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364 [TBL] [Abstract][Full Text] [Related]
3. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma. David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
6. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960 [TBL] [Abstract][Full Text] [Related]
7. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867 [TBL] [Abstract][Full Text] [Related]
8. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Petrella BL; Brinckerhoff CE Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472 [TBL] [Abstract][Full Text] [Related]
9. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971 [TBL] [Abstract][Full Text] [Related]
10. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases. Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808 [TBL] [Abstract][Full Text] [Related]
11. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Carroll VA; Ashcroft M Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202 [TBL] [Abstract][Full Text] [Related]
12. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Raval RR; Lau KW; Tran MG; Sowter HM; Mandriota SJ; Li JL; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ Mol Cell Biol; 2005 Jul; 25(13):5675-86. PubMed ID: 15964822 [TBL] [Abstract][Full Text] [Related]
13. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR. Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411 [TBL] [Abstract][Full Text] [Related]
14. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy. Yamasaki T; Kamba T; Kanno T; Inoue T; Shibasaki N; Arakaki R; Yamada T; Kondo K; Kamoto T; Nishiyama H; Ogawa O; Nakamura E Cancer Sci; 2012 Nov; 103(11):2027-37. PubMed ID: 22931246 [TBL] [Abstract][Full Text] [Related]
15. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
17. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929 [TBL] [Abstract][Full Text] [Related]